Replies to post #38611 on OWC Pharmaceutical Research Corp (OWCP)

[TappyS]

Don't they have to get to and pass full phase 3 clinical trials in order to get full FDA approval? It's still too early for that! What does your nurse say about that?

[Mr_Shaw]

your "nurse" needs to go back to med school. No one said it was on the FDA approval list. It's in progress for the efficacy test first. Just because it may not pass the FDA approval in the U.S does not mean we won't see profit from other countries.


http://www.prnewswire.com/news-releases/one-world-cannabis-to-offer-new-alternative-treatment-for-chronic-pain-in-light-of-fdas-nsaids-warning-515275481.html

http://www.thecannabist.co/2016/09/28/israel-cannabis-research/63987/

[valueinvestorconso]

Lol

[Gypsy Trader]

Some people what cheap shares.Thats a funny story considering my wife is a nurse for 20 years.Dubiest post of the day.Go to school son

[Ortiz26]

LMAO yea we believe that.
And no one ever said this was FDA so get your lies corrected.

https://clinicaltrials.gov/ct2/show/NCT02976779

[I FAR I]

Plenty of proof here that OWCP is Legit...

https://www.insiderfinancial.com/owc-pharmaceutical-research-corp-otcmktsowcp-is-off-to-a-strong-2017-start/119130/

...Beyond psoriasis, OWC is also pushing a multiple myeloma candidate through early stage trials, with the goal of getting the asset in question into clinical studies before the end of this year. Multiple myeloma is a large unmet need both domestically in the US and abroad, and the news stream alone associated with getting a drug into the clinical phase that targets this condition is worth considerable upside to a company of OWC’s size.

Finally, OWC is also working on a sublingual tablet designed to offer physicians a measurable and quantifiable method of dosing patients with cannabis related treatments. The current primary dosing method is smoking, but most agree that this is very inefficient. It’s also tough to track from a physician perspective. OWC’s asset aims to resolve this problem, and the company is looking to carry it into clinical trials for a range of conditions – posttraumatic stress disorder, fibromyalgia and the above discussed multiple myeloma to name just three – over the coming 12 months.

http://www.owcpharma.com/press-releases/